The relationship between CSCs and drug resistance has already been thoroughly investigated [37, 38], and our data supported the potentially vital role of BTK in the drug resistance of NSCLC cells, regardless of their EGFR mutation status. This evidence concerns the gene EGFR and non-small cell lung carcinoma.